Indications
Therapeutic Asset Ratings
3,272 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Trastuzumab Deruxtecan
Major Salivary Gland Cancer
National Cancer Institute (NCI)
P1
CC
(43)
Trastuzumab Deruxtecan
Uterine Corpus Endometrial Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Trastuzumab Deruxtecan
Uterine Corpus Cancer
National Cancer Institute (NCI)
P1
CC
(43)
Triapine
Astrocytoma, IDH-Mutant, Grade 2
National Cancer Institute (NCI)
P1
CC
(43)
Triapine
Astrocytoma, IDH-Mutant, Grade 3
National Cancer Institute (NCI)
P1
CC
(43)
Triapine
Astrocytoma, IDH-Mutant, Grade 4
National Cancer Institute (NCI)
P1
CC
(43)
Triapine
IDH-Wildtype Glioblastoma
National Cancer Institute (NCI)
P1
CC
(43)
Tslpr-Cart
Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
P1
CC
(43)
Tslpr-Cart
B-Cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
P1
CC
(43)
Turalio
Acute Promyelocytic Leukemia
National Cancer Institute (NCI)
P1
CC
(43)
Tuvusertib
Endometrial Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Tuvusertib
Endometrial Clear Cell Adenocarcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Tuvusertib
Endometrial Endometrioid Adenocarcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Tuvusertib
Ovarian Clear Cell Adenocarcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Tuvusertib
Ovarian Endometrioid Adenocarcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Tuvusertib
Ovarian Serous Adenocarcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Tuvusertib
Ovarian Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Uproleselan
Therapy-Related Myeloid Neoplasm
National Cancer Institute (NCI)
P1
CC
(43)
Uproleselan
Myeloid Leukemia Associated With Down Syndrome
National Cancer Institute (NCI)
P1
CC
(43)
Uproleselan
Mixed Phenotype Acute Leukemia
National Cancer Institute (NCI)
P1
CC
(43)
Uproleselan
Myelodysplastic Syndrome
National Cancer Institute (NCI)
P1
CC
(43)
Vancomycin
Non-Small Cell Lung Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Veliparib
Endometrial Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Veliparib
Liver Failure
National Cancer Institute (NCI)
P1
CC
(43)
Veliparib
Lung Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Showing 3026 to 3050 of 3,272 assets
Previous
Page 122 of 131
Next